A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, Silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters

Journal of Biological Regulators and Homeostatic Agents

Volumn 28, Issue 2, 2014, Pages 317-324

  Derosa, Giuseppe ^a   Bonaventura, A ^a   Bianchi, L ^a   Romano, D ^a   D'Angelo, A ^a   Fogari, E ^a   Maffioli, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Inflammation; Lipid profile; Octasonol; Red yeast rice; Silybum marianum

Indexed keywords

ADOLESCENT; ADULT; BLOOD PROTEINS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MILK THISTLE; ORYZA SATIVA;

EID: 84905649884     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274(2):131-6.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362(6423):801-9. (Pubitemid 23132154)
4. McBride PE. Triglycerides and risk for coronary heart disease. JAMA 2007; 298(3):336-8. (Pubitemid 47080491)
5. Derosa G, Ferrari I, D'Angelo A, et al. Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. Heart Vessels 2009; 24(3):204-10.
6. Derosa G, Ferrari I, D'Angelo A, et al. Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. Microvasc Res 2010; 80(1):110-15.
7. Maggi FM, Raselli S, Grigore L, Redaelli L, Fantappie S, Catapano AL. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J Clin Endocrinol Metab 2004; 89(6):2946-50. (Pubitemid 38766390)
8. Cicero AF, Ferroni A, Ertek S. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin Drug Saf 2012; 11(5):753-66.
9. Derosa G, Cicero AFG, Fogari E, D'Angelo A, Bonaventura A, Maffioli P. Effects of n-3 PUFAs on insulin resistance after an oral fat load. Eur J Lipid Sci Technol 2011; 113(8):950-60.
10. Derosa G, Cicero AFG, Fogari E, D'Angelo A, Bonaventura A, Romano D, Maffioli P. n-3 PUFAs effects on post-prandial variation of metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol 2012; 6(6):553-64.
11. Cicero AFG, Derosa G, Parini A, Maffioli P, D'Addato S, Reggi A, Giovannini M, Borghi C. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res 2013;33:622-8.
12. Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012; 12(8):1113-24.
13. Derosa G, D'Angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther 2013; 13(4):475-82.
14. Derosa G, Bonaventura A, Bianchi L, Romano D, D'Angelo A, Fogari E, Maffioli P. Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents 2013; 27(3):709-20.
15. Derosa G, Bonaventura A, Bianchi L, Romano D, D'Angelo A, Fogari E, Maffioli P. Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther 2013; 13(11):1495-506.
16. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001; 7(2):133-9. (Pubitemid 32319321)
17. Skottová N, Vecera R, Urbánek K, Vána P, Walterová D, Cvak L. Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacol Res 2003; 47(1):17-26. (Pubitemid 36259618)
18. Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of new lipid-lowering agent. Am Heart J 2002; 143(2):356-65.
19. Proposed International Guidelines for Biomedical Research Involving Human Subjects. The Council for International Organisation of Medical Sciences. Geneva, 1982.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.
21. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17:151-83.
22. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368:33-47. (Pubitemid 43792418)
23. Derosa G, Avanzini MA, Geroldi D, et al. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 2005; 70(2):119-25.
24. Derosa G, D'Angelo A, Tinelli C, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007; 33(2):129-34.
25. Derosa G, D'Angelo A, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E, Cicero AF. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007; 22(6):361-70. (Pubitemid 350201431)
26. Derosa G, Cicero AF, Scalise F, Avanzini M A, Tinelli C, Peros E, Fogari E, D'Angelo A. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium 2007; 14(4-5):175-83. (Pubitemid 47543002)
27. Derosa G, Cicero AF, Scalise F, et al. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 2007; 14(1):45-51. (Pubitemid 46978769)
28. Derosa G, Maffioli P, D'Angelo A, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 2009; 32(2):E124-32.
29. Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008; 15(4):219-24.
30. Derosa G, D'Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13(3):227-31. (Pubitemid 44110588)